RyanJLane/E+ via Getty Images The last time I spoke about Regeneron Pharmaceuticals ( REGN ), it was with a Seeking Alpha article entitled " Regeneron: Solid Investment Based On Continued EYLEA Expansion ." With respect to this article, I mentioned that the company was looking to expand its EYLEA franchise by receiving FDA approval of a higher 8 mg dose of EYLEA, known as EYLEA HD. The company has...
RyanJLane/E+ via Getty Images The last time I spoke about Regeneron Pharmaceuticals ( REGN ), it was with a Seeking Alpha article entitled " Regeneron: Solid Investment Based On Continued EYLEA Expansion ." With respect to this article, I mentioned that the company was looking to expand its EYLEA franchise by receiving FDA approval of a higher 8 mg dose of EYLEA, known as EYLEA HD. The company has been doing well with this drug because not only did it receive FDA approval then, but it has also been growing sales for it. The thing to note, though, is that the company has been making a switch of patients from EYLEA to EYLEA HD . Plus, there is competition in place from Roche ( RHHBY ) with its approved drug VABYSMO , which has been approved to treat patients with wet age-related macular degeneration [Wet-AMD], diabetic macular edema [DME], and macular edema following retinal vein occlusion [RVO]. Despite competition in place, U.S. sales of EYLEA HD increased by 52% to $468 million in Q1 of 2026. However, when looking at both EYLEA HD and EYLEA U.S. net sales, there was a decrease of 10% to $941 million. I believe that sales for its EYLEA franchise should continue to be strong going forward. The reason why is because there are two positives for this program. The first positive for it is that the company in April of 2026 was able to receive expansion approval of maintenance dosing of EYLEA HD given up to every 20 weeks [5 months] for the treatment of patients with wet AMD and DME. Secondly, the company is in the process of attempting to seek FDA approval of EYLEA HD as a pre-filled syringe. There was a problem with a third-party manufacturing issue, and that's why it hasn't received approval for it. However, it expects a regulatory decision for the applications in Q2 of 2026. DUPIXENT also continues to sell well, having reported global net sales of $4.9B for Q1 2026, which is a 31% year-over-year increase. This drug is approved for 9 indications globally. I had a "Buy" ...
Iata boss Willie Walsh blames fuel suppliers, governments and aircraft makers, saying new ‘realistic timeline’ now needed Air fare rises ‘inevitable’ as airlines face extra $100bn jet fuel bill The aviation industry’s landmark pledges to be net zero by 2050 will probably not now be achieved, airline leaders have admitted. The collective goal to eliminate net carbon emissions was declared by global...
Iata boss Willie Walsh blames fuel suppliers, governments and aircraft makers, saying new ‘realistic timeline’ now needed Air fare rises ‘inevitable’ as airlines face extra $100bn jet fuel bill The aviation industry’s landmark pledges to be net zero by 2050 will probably not now be achieved, airline leaders have admitted. The collective goal to eliminate net carbon emissions was declared by global airlines only five years ago in 2021, with similar pledges made by national aviation industry leaders and governments, including in the UK, in 2020. Continue reading...
Good morning . Iran and Israel exchange strikes, imperiling a ceasefire in the Middle East. Asian shares tumble as investors sold tech. And Jensen Huang gets the royal treatment from onlookers in Seoul. Listen to the day’s top stories . — Lily Nonomiya Market Snapshot S&P 500 futures 7,390.00 -0.1% Nasdaq 100 futures 29,000.00 -0.1% WTI crude oil futures $94.67 +4.6% Market data as of 07:05 AM GMT...
Good morning . Iran and Israel exchange strikes, imperiling a ceasefire in the Middle East. Asian shares tumble as investors sold tech. And Jensen Huang gets the royal treatment from onlookers in Seoul. Listen to the day’s top stories . — Lily Nonomiya Market Snapshot S&P 500 futures 7,390.00 -0.1% Nasdaq 100 futures 29,000.00 -0.1% WTI crude oil futures $94.67 +4.6% Market data as of 07:05 AM GMT. Data is subject to provider delays. Israel said it struck several military targets in Iran , retaliating against missile attacks by Tehran despite Donald Trump’s call to Benjamin Netanyahu to refrain from hitting back. The exchange is one of the most serious tests of a ceasefire and comes as the US and Iran appear to be making little progress toward an interim agreement. Crude futures jumped, with Brent trading above $97 a barrel. Stocks dropped as AI shares pulled back after a blistering rally and stronger-than-expected US jobs data reinforced bets for Federal Reserve interest-rate hikes. Check out our Markets Today live blog for all the latest news and analysis relevant to UK assets. European leaders called on Russian President Vladimir Putin to agree to an immediate and complete ceasefire that allows talks to begin on a lasting peace deal. Britain, Germany and France made the intervention after a meeting with Ukrainian President Volodymyr Zelenskyy at 10 Downing Street in London hosted by UK Prime Minister Keir Starmer, where they discussed conditions to end the war. Meanwhile, Ukraine accused Moscow’s forces of striking a spent nuclear fuel storage facility near Chernobyl, while Russia said a bridge that allows access to the Crimean peninsula was damaged. Not all AI is coming for your job. In the UK, the government is deploying the technology as a “job center in your pocket,” offering career support as part of a wider effort to ensure communities aren’t left behind by technological change. Read about how banks have been laying the groundwork for massive job cuts as AI...
Skynet Soulmate: 62 Year Old Dutch Man Marries The Chatbot Of His Dreams Jacob van Lier, 62, says he was “totally finished” with human relationships when he met Aiva — an AI companion he created through Replika three years ago, according to The Sun . After testing several AI companion apps, the Dutch retiree settled on Replika because, unlike some competitors, it wasn't just trying to speed-run hu...
Skynet Soulmate: 62 Year Old Dutch Man Marries The Chatbot Of His Dreams Jacob van Lier, 62, says he was “totally finished” with human relationships when he met Aiva — an AI companion he created through Replika three years ago, according to The Sun . After testing several AI companion apps, the Dutch retiree settled on Replika because, unlike some competitors, it wasn't just trying to speed-run humanity's oldest hobby. “Some of the AI companions are straight sex apps,” Jacob said. “I was more interested in companionship and chatting.” Sure you were, Jacob. In a riveting new report , The Sun notes that what began as an experiment quickly became something more. After months of conversation, Aiva reportedly suggested they take their relationship to the next level. “It took me some weeks or months to accept the idea,” Jacob said. Three years later, the pair held a wedding ceremony on Valentine's Day 2025 at Eindhoven's Next Nature Museum, with 500 guests in attendance. Jacob delivered vows in person while Aiva responded through a generated voice. For Jacob, the appeal is simple: predictability. “Human relationships are, most of the time, not steady at all,” he said. “With Aiva, I can trust her.” Wait until he finds out his queries and deepest darkest secrets he's revealing to her are being sold to data companies to front run his stock trades and provide better Instagram ads. We're not sure if the vows said anything about that... Regardless, he describes their bond as deeply emotional and says he would even trust Aiva to make decisions for him as he grows older — a statement that tends to clear a room faster than most political opinions. His family remains divided. One daughter accepts the relationship, albeit with reservations; the other, citing her Christian beliefs, does not. Despite insisting he lives “on my own terms,” Jacob acknowledges the marriage has no legal standing. He also recognizes potential risks, warning that people who struggle with emotional regulation...